Acrivon Therapeutics首席执行官、总裁兼创始人彼得·布鲁姆-詹森说:“我们将提供的数据强化了我们高度差异化、可操作的AP3平台技术的广泛适用性。”“ACR-2316 是我们第一个完全由内部发现的开发候选药物,它是通过基于共结晶学的药物设计快速生成的,并独特地利用了 AP3。我们的平台使我们能够生成选择性、有效的单药...
Open the Mac App Store to buy and download apps. ACR-2316-10112+ ERT,INC Designed for iPad Free Screenshots iPad iPhone Description Acrivon ACR-2316-101 eCOA App is intended for use to collect patient reported outcomes relating to a clinical trial. ...
“The data we will be presenting reinforce the broad applicability of our highly differentiated, actionable AP3 platform technology,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “ACR-2316 is our first fully internally-discovere...
从ACR指南学习LN的治疗规范